Immunization Safety Office, Division of Health Care Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA 30333, USA.
Vaccine. 2010 Oct 21;28(45):7248-55. doi: 10.1016/j.vaccine.2010.09.021. Epub 2010 Sep 16.
The United States (US) influenza A (H1N1) 2009 monovalent (2009-H1N1) vaccination program began in October 2009. Reports to the vaccine adverse event reporting system (VAERS), a US spontaneous reporting system, were reviewed to identify potential rare events or unusual adverse event (AE) patterns after 2009-H1N1 vaccination. The adverse event profile after 2009-H1N1 vaccine in VAERS (∼10,000 reports) was consistent with that of seasonal influenza vaccines, although the reporting rate was higher after 2009-H1N1 than seasonal influenza vaccines, this may be, at least in part, a reflection of stimulated reporting. Death, Guillain-Barré syndrome and anaphylaxis reports after 2009-H1N1 vaccination were rare (each <2 per million doses administered).
美国（美国）甲型流感（H1N1）2009 单价（2009-H1N1）疫苗接种计划于 2009 年 10 月开始。对疫苗不良事件报告系统（VAERS）的报告进行了审查，VAERS 是美国的一个自发报告系统，以确定 2009-H1N1 疫苗接种后潜在的罕见事件或异常不良事件（AE）模式。VAERS 中 2009-H1N1 疫苗接种后的不良事件概况（约 10000 份报告）与季节性流感疫苗一致，尽管 2009-H1N1 疫苗接种后的报告率高于季节性流感疫苗，这可能至少部分反映了受刺激的报告。2009-H1N1 疫苗接种后的死亡、吉兰-巴雷综合征和过敏反应报告罕见（每百万接种剂量各<2 例）。
MMWR Morb Mortal Wkly Rep. 2009-12-11
Rev Inst Med Trop Sao Paulo. 2018-12-20
J Allergy Clin Immunol. 2016-3
Zotero 插件